News of the cutbacks, detailed in the drugmaker’s ‘Hayabusa’ strategy presentation , comes just months after its blockbuster Alzheimer’s drug lost patent protection in the US and four weeks after Ranbaxy launched a generic version of the product.
Overall Eisai said it aims to generate revenue of 800bn yen ($9.8bn) in the financial year 2015, with growth of the East Asia and emerging markers India, Brazil, Russia and Canada being its key drivers.